LCI may have a role in the routine clinical care of both adult and pediatric CF patients as a good tool to assess response to IV antibiotic end-therapy in the same way as FEV1.
Keyphrases
- cystic fibrosis
- end stage renal disease
- newly diagnosed
- healthcare
- ejection fraction
- chronic kidney disease
- pseudomonas aeruginosa
- chronic obstructive pulmonary disease
- palliative care
- peritoneal dialysis
- pulmonary hypertension
- prognostic factors
- lung function
- bone marrow
- intensive care unit
- mesenchymal stem cells
- patient reported outcomes
- cell therapy
- air pollution